Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 0.5% - Should You Sell?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was down 0.5% on Wednesday . The company traded as low as $1.96 and last traded at $2.03. Approximately 30,466 shares were traded during mid-day trading, a decline of 56% from the average daily volume of 69,576 shares. The stock had previously closed at $2.04.

Analyst Upgrades and Downgrades

Separately, HC Wainwright increased their price target on Armata Pharmaceuticals from $7.00 to $9.00 and gave the company a "buy" rating in a report on Monday, May 19th.

Armata Pharmaceuticals Trading Down 1.0%

The company has a market capitalization of $72.72 million, a price-to-earnings ratio of -1.23 and a beta of 0.87. The company has a 50-day moving average of $1.55.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.